

Rabbit Anti-CD30 (Ki-1 Antigen) [MD186R]: RM0036, RM0036RTU7

Intended Use: For Research Use Only

Description: CD30, TNF-receptor superfamily member, is a receptor for TNFSF8/CD30L. TRAF2 and TRAF5 can interact with this receptor and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and it also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. The CD30 antibody labels activated B and T cells. It has been useful in identifying Hodgkin's lymphoma, anaplastic large cell lymphomas (ALCL) and primary cutaneous CD30+ T-cell lymphoproliferative disorders. In non-lymphoid malignancies, CD30 reactivity has been reported in embryonal carcinomas (ECs), seminomas, and hepatocellular carcinomas.

Specifications


Clone:	MD186R
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Immunogen:	Recombinant human full-length TNFRSF8 protein
Localization:	Membrane
Formulation:	Purified antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C.
Applications:	IHC
Package:	

Description	Catalog No.	Size
CD30 (Ki-1 Antigen) Concentrated	RM0036	1 ml
CD30 (Ki-1 Antigen) Prediluted	RM0036RTU7	7 ml

IHC Procedure*

Positive Control Tissue:	Tonsil, Hodgkin's lymphoma
Concentrated Dilution:	50-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human Hodgkin's Lymphoma stained with anti-CD30 using DAB

References

1. The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma. Xiaoxiao Hao , et al. Plos One. May 14, 2015.
2. Primary Cutaneous CD8(+) CD30(+) Anaplastic Large Cell Lymphoma: An Unusual Case with a High Ki-67 index-A Short Review. Nasit JG, et al. Indian J Dermatol. Jul-Aug;60(4):373-7, 2015.
3. Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Vallacchi V, et al. Cancer Res. Jan 1;74(1):130-40, 2014.